Combining RT-PCR, clinical symptoms, and serological screening ensures timely and accurate diagnosis, especially in pregnant women. less than 0.05. Variables in bivariate analysis of chi-square that have a P-value less than 0.2 were entered into a logistic regression using multivariate logistic models. Results: The study detected active COVID-19 infections among 7.4% (19/258) of the study participants. The study exhibited a seroprevalence of COVID-19 antibodies in 62.4% (161/258) of the participants at recruitment and showed a strong correlation between working in the healthcare setting and living in an urban environment. Our study also reported 5.3% (8/152) of cord blood antibody positivity among study participants. The concentration of maternal immunoglobulin strongly and positively correlated with cord blood seropositivity. Conclusion: Prevalence estimates are an underestimate of the actual proportion of pregnant women with prior COVID-19 exposure as Mmp10 observed in the study discrepancy of confirmed PCR contamination and evidence of previous contamination from serology. The study also highlighted a low efficiency of placental transfer of COVID-19 antibodies at birth among those who were seropositive at baseline and showed that maternal antibody levels play Rimantadine (Flumadine) an important role in determining the efficiency of placenta transfer of COVID-19 antibodies in pregnancy. Keywords:polymerase chain reaction, antibody transfer, covid-19, pregnancy, seroprevalence == Introduction == COVID-19, a potentially severe acute respiratory infection, is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1,2]. COVID-19 manifestation spans from symptomatic to asymptomatic, with a majority of the infections going undiagnosed and unreported [3]. Consequently, relying solely on clinically apparent cases significantly underestimates the true infection rates. The existence of asymptomatic or subclinical infections raises concerns due to their potential for propagating the Rimantadine (Flumadine) infection, which poses significant challenges to public health efforts. Serologic tests detect COVID-19-specific antibodies, indicating previous exposure regardless of symptom severity [4,5]. Monitoring seropositivity in a population reveals the infection extent. In pregnancy, viral infections pose risks due to altered immune status, increasing vulnerability to adverse outcomes [6]. Viral infections such as influenza, Lassa fever, and Ebola have elevated mortality rates for pregnant women and fetuses [7-9]. Despite extensive COVID-19 research, significant knowledge gaps remain, especially regarding pregnancy, with limited studies in Africa. Unfortunately, pregnant women are often excluded from the research on vaccines and treatments for emerging infectious diseases due to concerns about fetal risks, despite the threats posed by COVID-19 to mothers and healthcare workers [10,11]. It is crucial to recognize pregnant women as a unique and vulnerable group deserving specific research attention for COVID-19 and other emerging diseases. Moreover, understanding its effects during pregnancy remains limited, with emerging evidence suggesting a substantial portion of pregnant women are asymptomatic [12]. While numerous COVID-19 vaccines are in development, lacking comprehensive epidemiological data hampers trial design, with gaps in understanding seroprevalence, infection rates, high-risk groups, disease presentations, and antibody kinetics. It is also approximated that 80% of infections are mild or asymptomatic [13]. Therefore, relying solely on confirmed cases may underestimate the true disease burden and infection fatality rate. Serological tests are, therefore, recommended for the detection of specific antibodies, as this will provide an accurate estimate of infections [14-20]. A recent New York City-based study conducted between March and April 2020 found that 36% of the suspected COVID-19 pregnant patients tested positive [21]. In sub-Saharan Africa, asymptomatic pregnant women are rarely tested, hindering disease burden assessment. Pregnant women’s frequent interactions heighten risks for healthcare workers and the public, warranting their classification as a “special group” in COVID-19 interventions. Nigeria’s testing is mainly for symptomatic patients, potentially underestimating the COVID-19 disease burden. Philadelphia research reported 1.4% PCR-confirmed COVID-19 cases in pregnant women, contrasting serological studies showing a higher 6.2% exposure rate [22-26]. A Nigerian household seroprevalence survey revealed higher infection rates than national data, particularly in asymptomatic cases [25]. This survey found COVID-19 antibodies in 23% (Lagos state) and 9% (Gombe state), indicating substantial exposure [25]. Seroprevalence surveys effectively estimate population exposure. Serology testing is gaining importance in detecting COVID-19 exposure and transmission. Patients typically show positive IgG or IgM antibody results within 19 days of SARS-CoV-2 exposure, even after negative PCR results [27-31]. Pregnant women Rimantadine (Flumadine) and neonates have unique immune systems shaped by maternal-fetal interactions. The extent of passive transfer of COVID-19 antibodies.